PRTK Paratek Pharmaceuticals Inc.

23.35
-0.90  -4%
Previous Close 24.25
Open 24.20
Price To book 5.72
Market Cap 648223740
Shares 27,761,188
Volume 333,825
Short Ratio 4.67
Av. Daily Volume 642,618

SEC filingsSee all SEC filings

  1. 8-K - Current report 171009340
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 17997971
  3. 8-K - Current report 17967654
  4. 8-K - Current report 17936671
  5. S-8 - Securities to be offered to employees in employee benefit plans 17920881

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved November 23, 2011.
Intermezzo
Insomnia
Phase 3 data released July 17, 2017 - all endpoints met.
Omadacycline - oral
Acute bacterial skin and skin structure infections (ABSSSI)
Phase 3 topline data met endpoints - June 2016
Omadacycline
Acute bacterial skin and skin structure infections (ABSSSI)
Phase 3 data released April 3, 2017 - all endpoints met. Regulatory filing due 1Q 2018.
Omadacycline
Community-acquired bacterial pneumonia (CABP)
Phase 3 data released March 27 2017 - primary endpoints met. NDA filing due 2H 2017.
Sarecycline
Severe acne vulgaris

Latest News

  1. Paratek Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PRTK) : October 18, 2017
  2. Paratek Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PRTK-US : October 17, 2017
  3. Today's Research Reports on Stocks to Watch: Paratek Pharmaceuticals and 22nd Century Group
  4. Paratek Shares Higher on Microbiology Data -- Biotech Movers
  5. Paratek Pharma shares surge 6% on late-stage results for antibiotic
  6. Phase 3 Optic Study Microbiology Data Demonstrate Omadacycline has Potent In vitro Activity Against Multiple Pneumonia Pathogens, Including Resistant Bacteria
  7. Consistent Efficacy and Safety Profile Observed in New Analyses of OASIS-1 Phase 3 Study of Omadacycline in Patients with Difficult to Treat Comorbid Conditions
  8. Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
  9. Paratek Pharmaceuticals to Present New Omadacycline Data at IDWeek 2017
  10. Omadacycline Receives Qualified Infectious Disease Product Designation from FDA for an Additional Indication in Uncomplicated Urinary Tract Infections
  11. Why Nabriva Therapeutics Shares Are Falling Today
  12. Paratek Pharmaceuticals, Inc. to Host Investor Day on October 17, 2017
  13. Nabriva's Lefamulin Positive in Pivotal Study, Stock Surges
  14. Why Nabriva Therapeutics PLC Is Skyrocketing
  15. Paratek Pharmaceuticals, Inc. (PRTK) Catches Eye: Stock Up 27.3%
  16. Paratek Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PRTK-US : August 24, 2017
  17. Today's Research Reports on Stocks to Watch: Paratek Pharmaceuticals Inc. and Ultragenyx Pharmaceutical Inc.
  18. Here's Why Paratek Pharmaceuticals Soared as Much as 37% Today
  19. Paratek Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences